Patents by Inventor Michael Kirchengast

Michael Kirchengast has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Endothelin antagonist and beta receptor blocking agent as combined preparations
    Patent number: 6352992
    Abstract: A combination of endothelin antagonists and beta-receptor blockers is described. The combination is suitable for controlling diseases.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: March 5, 2002
    Assignee: Abbott Laboratories
    Inventors: Michael Kirchengast, Klaus Münter
  • Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
    Patent number: 6329384
    Abstract: A combination of endothelin antagonists and RAS inhibitor is described. The combination is suitable for controlling diseases.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: December 11, 2001
    Assignee: Abbott Laboratories
    Inventors: Klaus Münter, Michael Kirchengast, Horst Korioth
  • Method for combating obesity
    Patent number: 6197780
    Abstract: Diseases caused by obesity are treated with endothelin receptor antagonists. Diseases treated include those frequently associated with obesity such as hypertension, type 2 diabetes, hyperlipidemia, chronic kidney failure, arteriosclerosis and gout.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: March 6, 2001
    Assignee: Knoll Aktiengesellschaft
    Inventors: Klaus Münter, Michael Kirchengast
  • Substituted N-phenylpiperidines and drugs therefrom
    Patent number: 5296485
    Abstract: Substituted N-phenylpiperidines I ##STR1## (R.sup.1 =H, NO.sub.2, CN, halogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, OCF.sub.3, OH, CH.sub.2 OH, COOH, CHO, NH--CHO, NH.sub.2, CO--NH.sub.2, 5-tetrazinyl, R.sup.4 --O--, R.sup.4 --O--CH.sub.2 --, R.sup.4 O--CO--, R.sup.4 --CO--, R.sup.4 --NH--CO, R.sup.4 --CO--NH--, R.sup.4 --SO.sub.2 --NH--;R.sup.2 =H, NO.sub.2, halogen, C.sub.1 -C.sub.4 -alkyl or R.sup.4 --O--; ##STR2## R.sup.4 =C.sub.1 -C.sub.4 -alkyl or phenyl which can carry one of the R.sup.2 radicals;R.sup.5, R.sup.6 =H or one of the R.sup.4 radicals; R.sup.7 =one of the R.sup.1 radicals;n=0 or 1; m=1 or 2; with the proviso that R.sup.3 is ##STR3## only when n is 1, and the optical isomers in the case of optical isomerism, and the physiologically tolerated acid addition salts, are suitable as drugs.
    Type: Grant
    Filed: March 11, 1992
    Date of Patent: March 22, 1994
    Assignee: BASF Aktiengesellschaft
    Inventors: Wilfried Lubisch, Sabine Schult, Berthold Behl, Michael Kirchengast
  • Substituted anilides
    Patent number: 5260330
    Abstract: Substituted anilides of the formula I ##STR1## (where R.sup.1 is C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, halogen, cyano, nitro, C.sub.2 -C.sub.4 -alkenyl, C.sub.2 -C.sub.4 -alkynyl;X is methylene, ethylene, vinylene;R.sup.2 and R.sup.3 are each C.sub.1 -C.sub.4 -alkyl, C.sub.3 -C.sub.6 -cycloalkyl or together are tetra- or pentamethylene;R.sup.4 is C.sub.1 -C.sub.4 -alkyl, methoxy;n is 2, 3 or 4),and the physiologically tolerated acid addition salts thereof, the pharmaceutical use thereof, drugs produced therefrom and the use thereof for treating cardiac arrhythmias and/or for lowering the heart rate, are described.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: November 9, 1993
    Assignee: BASF Aktiengesellschaft
    Inventors: Wilfried Lubisch, Gerda von Philipsborn, Sabine Schult, Michael Kirchengast